Lingzhi(Ganoderma) is widely used in traditional Chinese medicine. Previous studies indicated that Lingzhi was safe, well tolorated, and improved symptoms as an add-on therapy to levodopa in early Parkinson's disease(PD) patients. Here the investigators design a multicenter, randomized, double-blind, placebo-controlled, delayed-start trial to evaluate the effects of Lingzhi on modifying disease progression in untreated PD patients.

Inclusion Criteria:

• Meeting the criteria for "Probable Parkinson's disease" according to 2015 MDS Clinical Diagnostic Criteria for Parkinson's Disease
• Aged 30-80 years
• Hoehn-Yahr Stage≤2
• UPDRS Part III subscores ranging from 10 to 30 points
• Disease duration of 5 years or less
• Untreated with antiparkinsonian drugs for at least two weeks preceding the trial
• Willing to sign the written informed consent

Exclusion Criteria:

• Atypical or secondary parkinsonism
• With psychiatric symptoms or a history of psychiatric diseases
• With cognitive impairment(MMSE score<24)
• Major liver or kidney dysfunction
• Participating in other clinical trials within 3 months preceding the current trial